Medical Patent News

RSS

Arcion receives U.S. patent allowance for ARC-2022 to treat PHN

Arcion Therapeutics, a clinical stage biotechnology company developing topical therapies for chronic pain, today announced that it received notice of allowance for a US Patent for its high strength gel formulation of topical lidocaine, ARC-2022.

5 Jan 2012

NovaSterilis awarded soft tissue processing patent

NovaSterilis Inc., specializing in developing applications for supercritical carbon dioxide, has been granted US Patent 8,034,288 B2. The patent, dated October 11, 2011 entitled “Method and Apparatus for Cleaning of Viable Donor Soft Tissue”, covers a new method for cleaning soft allograft tissue including tendon, fascia, and skin with a supercritical fluid, thus avoiding other harmful chemical solvents that may leave residual chemicals.

4 Jan 2012

J&J will not join Medicines Patent Pool; Company's pharma head says mechanism could 'cause disaster'

Pharmaceutical company "Johnson & Johnson has rejected calls to offer patent rights on its HIV medicines to generic drug companies through a" Medicines Patent Pool, created to promote low-cost antiretroviral drugs in low-income countries and the development of new drug combinations and formulations, the Financial Times reports.

4 Jan 2012

USPTO issues patent to NJIT's unique device for treatment of brain injury

NJIT Professor Gordon Thomas and NJIT Research Professor Reginald Farrow, both in the department of physics, and NJIT alumnus Sheng Liu, formerly a doctoral student of both researchers and now an engineer at a biotech company, were awarded a patent today for the NJIT SmartShunt-, a unique device to help patients with brain injuries.

4 Jan 2012

Regeneron, Genentech enter non-exclusive license and partial settlement agreement for EYLEA

Regeneron Pharmaceuticals, Inc. today announced that the Company has entered into a non-exclusive license and partial settlement agreement with Genentech, Inc., a member of the Roche Group relating to U.S. ophthalmic sales of EYLEA (aflibercept) Injection.

3 Jan 2012

ARCA biopharma extends pharmacogenetic intellectual property protection around bucindolol

ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the U.S. Patent and Trademark Office has issued a patent on methods for treating patients with bucindolol based on genetic targeting and focused on a specific genotype - homozygous wildtype for Deletion 322-325 in the alpha-2C adrenergic receptor.

31 Dec 2011

USPTO issues patent to Novus Scientific's TIGR Matrix Surgical Mesh

The Intellectual Property portfolio of TIGR Matrix Surgical Mesh has been further complimented with the granting of a second U.S. patent related to material degradation and mechanical behaviour.

27 Dec 2011

Acacia increases infusion pump technology patent portfolio

Acacia Research Corporation announced that a subsidiary has acquired patents relating to infusion pump technology from a major medical device company.

19 Dec 2011

Supreme Court hears arguments related to patent dispute

The Minneapolis Star Tribune reports that the question is whether patents can be applied to concepts drawn from nature and notes that the case could redefine ownership of technological or scientific innovations.

9 Dec 2011

USPTO issues Diabetes Patent to Omni Bio

Omni Bio Pharmaceutical, Inc. today announced that U.S. Patent No. 8,071,551, entitled "METHODS AND COMPOSITIONS FOR TREATING DIABETES," was issued by the United States Patent and Trademark Office on December 6, 2011. The Diabetes Patent expires in May 2022.

9 Dec 2011

Ampio awarded composition of matter patent for Ampion in Europe

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, today announced receipt of notification of the granting of a European patent with broad claims directed to compositions containing DA-DKP, a cyclic dipeptide diketopiperazine which is the active ingredient of Ampion™.

7 Dec 2011

ZIOPHARM receives European patent allowance for palifosfamide to treat cancer

ZIOPHARM Oncology, Inc. announced today that it has received an allowance from the European Patent Office for Patent Application No. 05 821 125.1, entitled "Salts of Isophosphoramide mustard and analogs thereof as anti-tumor agents" with claims directed to pharmaceutical compositions of a novel DNA cross-linker, including palifosfamide and their use in treating cancer.

7 Dec 2011

NASA-developed technology for treatment of hardened arteries in the heart

NASA has signed a patent license agreement that will allow a California company use of NASA-developed technology that could be used to treat hardened arteries in the heart.

3 Dec 2011

Mylan confirms generic Generess Fe patent challenge

Mylan Inc. today confirmed that it and Famy Care Ltd. have been sued by Warner Chilcott Company LLP, in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Norethindrone and Ethinyl Estradiol Chewable Tablets, 0.8 mg/0.025 mg and Ferrous Fumarate Chewable Tablets. This product is the generic version of Generess Fe, a 28-day regimen indicated for use by women to prevent pregnancy.

2 Dec 2011